Logo image of NVIV

INVIVO THERAPEUTICS HOLDINGS (NVIV) Stock Fundamental Analysis

NASDAQ:NVIV - Nasdaq - US46186M6057 - Common Stock - Currency: USD

0.3207  -0.17 (-34.28%)

After market: 0.231 -0.09 (-27.97%)

Fundamental Rating

2

Taking everything into account, NVIV scores 2 out of 10 in our fundamental rating. NVIV was compared to 187 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for NVIV as it has an excellent financial health rating, but there are worries on the profitability. NVIV is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NVIV had negative earnings in the past year.
In the past year NVIV has reported a negative cash flow from operations.
NVIV had negative earnings in each of the past 5 years.
NVIV had a negative operating cash flow in each of the past 5 years.
NVIV Yearly Net Income VS EBIT VS OCF VS FCFNVIV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -97.39%, NVIV is doing worse than 82.32% of the companies in the same industry.
With a Return On Equity value of -104.60%, NVIV is not doing good in the industry: 71.21% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -97.39%
ROE -104.6%
ROIC N/A
ROA(3y)-47.54%
ROA(5y)-79.37%
ROE(3y)-56.17%
ROE(5y)-105.18%
ROIC(3y)N/A
ROIC(5y)N/A
NVIV Yearly ROA, ROE, ROICNVIV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NVIV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NVIV Yearly Profit, Operating, Gross MarginsNVIV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022

More info and screens

7

2. Health

2.1 Basic Checks

NVIV has more shares outstanding than it did 1 year ago.
NVIV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NVIV Yearly Shares OutstandingNVIV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M
NVIV Yearly Total Debt VS Total AssetsNVIV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -38.75, we must say that NVIV is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -38.75, NVIV is not doing good in the industry: 92.93% of the companies in the same industry are doing better.
NVIV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -38.75
ROIC/WACCN/A
WACCN/A
NVIV Yearly LT Debt VS Equity VS FCFNVIV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 14.22 indicates that NVIV has no problem at all paying its short term obligations.
NVIV has a better Current ratio (14.22) than 95.45% of its industry peers.
A Quick Ratio of 14.22 indicates that NVIV has no problem at all paying its short term obligations.
The Quick ratio of NVIV (14.22) is better than 95.96% of its industry peers.
Industry RankSector Rank
Current Ratio 14.22
Quick Ratio 14.22
NVIV Yearly Current Assets VS Current LiabilitesNVIV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 56.05% over the past year.
EPS 1Y (TTM)56.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.06%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NVIV Yearly EPS VS EstimatesNVIV Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 -5K -10K -15K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NVIV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NVIV Price Earnings VS Forward Price EarningsNVIV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NVIV Per share dataNVIV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NVIV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INVIVO THERAPEUTICS HOLDINGS

NASDAQ:NVIV (2/12/2024, 8:01:31 PM)

After market: 0.231 -0.09 (-27.97%)

0.3207

-0.17 (-34.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-09 2023-08-09
Earnings (Next)N/A N/A
Inst Owners0.76%
Inst Owner Change-0.01%
Ins Owners557.87%
Ins Owner Change0%
Market Cap997.38K
Analysts85.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.11
P/tB 0.11
EV/EBITDA N/A
EPS(TTM)-3.52
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-3.27
FCFYN/A
OCF(TTM)-3.26
OCFYN/A
SpS0
BVpS2.86
TBVpS2.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -97.39%
ROE -104.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.54%
ROA(5y)-79.37%
ROE(3y)-56.17%
ROE(5y)-105.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 100%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.22
Quick Ratio 14.22
Altman-Z -38.75
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)182.22%
Cap/Depr(5y)128.22%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.06%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.64%
OCF growth 3YN/A
OCF growth 5YN/A